Assignee
CELLACT PHARMA GMBH
DE·4 granted patents·3 pending applications·4 citations·filing 2002–2023
Top patents by PatentIndex Score
7 records- 0168US9827261B2Etoposide and prodrugs thereof for use in targeting cancer stem cellsCELLACT PHARMA GMBH·Filed 2014·Granted Nov 28, 2017·1 cites·9 claims
- 0264US7794715B2Anti-TIRC7 antibodies in therapy of inflammatory diseasesCELLACT PHARMA GMBH·Filed 2002·Granted Sep 14, 2010·3 cites·4 claims
- 0363US2009175879A1Novel target in the treatment of cytokine release syndromeCELLACT PHARMA GMBH·Filed 2007·Application pending·0 cites
- 0452US11892454B2Method for the diagnosis of etoposide prodrug treatable cancerCELLACT PHARMA GMBH·Filed 2018·Granted Feb 6, 2024·0 cites·5 claims
- 0552US10183035B2Etoposide and prodrugs thereof for use in targeting cancer stem cellsCELLACT PHARMA GMBH·Filed 2017·Granted Jan 22, 2019·0 cites·10 claims
- 0648US2026000695A1Solid and oral etoposide toniribate compositionsCELLACT PHARMA GMBH·Filed 2023·Application pending·0 cites
- 0741US2023398069A1Etoposide toniribate formulationCELLACT PHARMA GMBH·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →